Sorrento Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 949
- Market Cap
- -
Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors
- Conditions
- Refractory CancerSolid Tumor, AdultRelapsed Solid Neoplasm
- Interventions
- Biological: STI-3258
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT05060276
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Biological: STI-1492
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT05007418
- Locations
- 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸UC Davis, Sacramento, California, United States
🇺🇸UC Irvine, Orange, California, United States
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise
- Conditions
- Covid19
- Interventions
- Biological: PlaceboBiological: COVI-MSC
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT04992247
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
- Conditions
- Acute Respiratory Distress SyndromeArds
- Interventions
- Biological: COVI-MSCDrug: Placebo
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT04909879
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise
- Conditions
- Covid19
- Interventions
- Biological: COVI-MSC
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT04909892
Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)
- Conditions
- Covid19
- Interventions
- Drug: PlaceboBiological: COVI-DROPS
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT04906694
- Locations
- 🇺🇸
Centex Studies Inc. Houston, Houston, Texas, United States
🇺🇸Clinical Site Partners, Inc, Winter Park, Florida, United States
🇺🇸Remington Davis, Columbus, Ohio, United States
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress
- Conditions
- Covid19
- Interventions
- Drug: PlaceboBiological: COVI-MSC
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04905836
- Locations
- 🇺🇸
St Luke's Research, Boise, Idaho, United States
🇺🇸St. Luke's Boise, Boise, Idaho, United States
🇺🇸Teradan Clinical Trials LLC, Brandon, Florida, United States
Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress
- Conditions
- Covid19
- Interventions
- Biological: COVI-MSCDrug: Placebo
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT04903327
- Locations
- 🇧🇷
Hospital São Rafael S.A. - Instituto D'Or de Pesquisa e Ensino, Salvador, BA, Brazil
🇧🇷Saraiva & Berlinger Ltda. - EPP (IPECC), Campinas, SP, Brazil
🇧🇷Santa Casa de Misericórdia da Bahia (Hospital Santa Izabel), Salvador, BA, Brazil
Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)
- Conditions
- Covid19
- Interventions
- Biological: COVI-DROPSDrug: Placebo
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 179
- Registration Number
- NCT04900428
- Locations
- 🇬🇧
University Hospitals of Coventry and Warwickshire Hospital Trust, Coventry, United Kingdom
Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors
- Conditions
- Solid TumorRelapsed Solid NeoplasmRefractory Tumor
- Interventions
- Biological: STI-6643
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04900519
- Locations
- 🇺🇸
Sanford Health, Sioux Falls, South Dakota, United States
🇺🇸University of California, San Diego, San Diego, California, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States